

Associate professor Dániel Aradi

1. Sibbing D*, Aradi D*, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Hadamitzky M, Merkely B, Kiss RG, Komócsi A, Dézsi CA, Holdt L, Felix SB, Parma R, Klopotoski M, Schwinger RHG, Rieber J, Huber K, Neumann FJ, Koltowski L, Mehilli J, Huczek Z, Massberg S; TROPICAL-ACS Investigators. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. *Lancet*. 2017;390:1747-1757. *: authors contributed equally.
2. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur Heart J*. 2015;36:1762-71.
3. Aradi D, Collet JP, Mair J, Plebani M, Merkely B, Jaffe AS, Möckel M, Giannitsis E, Thygesen K, ten Berg JM, Mueller C, Storey RF, Lindahl B, Huber K; Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association of the European Society of Cardiology; Working Group on Thrombosis of the European Society of Cardiology. Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding? *Thromb Haemost*. 2015;113:221-30.
4. Aradi D, Tornoyos A, Pintér T, Vorobcsuk A, Kónyi A, Faluközy J, Veress G, Magyari B, Horváth IG, Komócsi A. Optimizing P2Y12-receptor inhibition in acute coronary syndrome patients based on platelet function testing: impact of prasugrel and high-dose clopidogrel. *J Am Coll Cardiol* 2014;63:1061-70.
5. Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG, Husted S, Bonello L, Sibbing D, Collet JP, Huber K, on behalf of the Working Group on Thrombosis of the European Society of Cardiology. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention *Eur Heart J* 2014;35:209-15.

Prof. Dr, med. Tobias Geisler, FESC, MHBA

6. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Sarahl R, Nordbeck P, Geisler T, Landmesser U, Skurk C, Fach A, Lapp H, Piek JJ, Noc M, Goslar T, Felix SB, Maier LS, Stepinska J, Oldroyd K, Serpytis P, Montalescot G, Barthelemy O, Huber K, Windecker S, Savonitto S, Torremante P, Vrints C, Schneider S, Desch S, Zeymer U; CULPRIT-SHOCK Investigators. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. *N Engl J Med*. 2017;377(25):pp. 2419-2432.
7. Chatterjee M, Rath D, Schlotterbeck J, Rheinlaender J, Walker-Allgaier B, Alnaggar N, Zdanyte M, Müller I, Borst O, Geisler T, Schäffer TE, Lämmerhofer M, Gawaz M. Regulation of oxidized platelet lipidome: implications for coronary artery disease. *Eur Heart J*. 2017;38(25):pp. 1993-2005.
8. Geisler T, Poli S, Meisner C, Schreieck J, Zuern CS, Nägele T, Brachmann J, Jung W, Gahn G, Schmid E, Bäckner H, Keller T, Petzold GC, Schrickel JW, Liman J, Wachter R, Schön F, Schabet M, Lindner A, Ludolph AC, Kimmig H, Jander S, Schlegel U, Gawaz M, Ziemann U. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design. *Int J Stroke*. 2017;12(9):pp. 985-990.
9. Rath D, Chatterjee M, Borst O, Müller K, Stellos K, Mack AF, Bongartz A, Bigalke B, Langer H, Schwab M, Gawaz M, Geisler T. Expression of stromal cell-derived factor-1 receptors CXCR4 and CXCR7 on circulating platelets of patients with acute coronary syndrome and association with left ventricular functional recovery. *Eur Heart J*, 2014;35(6): pp.386-394.
10. Geisler T; Langer H; Wydymus M; Göhring K; Zürn C; Bigalke B; Stellos K; May AE; Gawaz M; Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. *Eur Heart J*, 2006 27 (20): pp.2420-2425.

Associate Professor Bruna Gigante, MD

11. Marklund M, Leander K, Vikström M, Laguzzi F, Gigante B, Sjögren P, Cederholm T, de Faire U, Hellénus ML, Risérus U. Polyunsaturated Fat Intake Estimated by Circulating Biomarkers and Risk of Cardiovascular Disease and All-Cause Mortality in a Population-Based Cohort of 60-Year-Old Men and Women. *Circulation*. 2015 Aug 18;132(7):586-94. PMID: 26085453.
12. Moreno Velasquez I, Golabkesh Z, Källberg H, Leander K, de Faire U, Gigante B. Circulating levels of Interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction. *Atherosclerosis* 2015;240:477-481. PMID: 25910182
13. Velásquez IM, Frumento P, Johansson K, Berglund A, de Faire U, Leander K, Gigante B. Association of interleukin 8 with myocardial infarction: results from the Stockholm Heart Epidemiology Program. *Int J Cardiol*. 2014;172:173-8. PubMed PMID: 24462138.
14. Gigante B, Leander K, Vikström M, Baldassarre D, Veglia F, Strawbridge RJ, McLeod O, Gertow K, Sennblad B, Shah S, Zabaneh D, Humphries SE, Kauhanen J, Rauramaa R, Smit AJ, Mannarino E, Giral P, Tremoli E, Hamsten A, Frostegård J, de Faire U; IMPROVE Study Group. Low levels of IgM antibodies against phosphorylcholine are associated with fast carotid intima media thickness progression and cardiovascular risk in men. *Atherosclerosis*. 2014;236:394-9. PMID: 25150937.
15. Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med*. 2013;368:987-98. PMID: 23484825.

Prof Diana Gorog, MB BS, MD, PhD, FRCP

1. Christopoulos C, Farag M, Sullivan K, Wellsted D, Gorog DA. Impaired Thrombolytic Status Predicts Adverse Cardiac Events in Patients Undergoing Primary Percutaneous Coronary Intervention. *Thrombosis and Haemostasis* 2016 Dec 22. doi: 10.1160/TH16-09-0712
2. Okafor ON, Gorog DA. Endogenous Fibrinolysis: An Important Mediator of Thrombus Formation and Cardiovascular Risk. *J Am Coll Cardiol*. 2015;65(16):1683-1699.
3. Rosser G, Tricoci P, Morrow D, Christopoulos C, Niespialowska-Steuden MN, Kozarski R, Wilcox R, Gorog DA. PAR-1 antagonist vorapaxar favorably improves global thrombotic status in patients with coronary disease. *J Thromb Thrombolysis*. 2014;38(4):423-9.
4. Gorog DA & Fuster V. Platelet function tests in clinical cardiology: unfulfilled expectations. *J Am Col Cardiol*. 2013;61(21):2115-29.
5. Sharma S, Farrington K, Kozarski R, Christopoulos C, Niespialowska-Steuden M, Moffat D, Gorog DA. Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. *Eur Heart J*. 2013;34(5):354-63.

Associate Professor Erik L. Grove, MD, PhD

1. Hansson NC, Grove EL, Andersen HR, Leipsic J, Mathiassen ON, Jensen JM, Jensen KT, Blanke P, Leetmaa T, Tang M, Krusell LR, Klaborg KE, Christiansen EH, Terp K, Terkelsen CJ, Poulsen SH, Webb J, Bøtker HE, Nørgaard BL. Transcatheter Aortic Valve Thrombosis: Incidence, Predisposing Factors, and Clinical Implications. *J Am Coll Cardiol*. 2016 Nov 8;68(19):2059-2069. doi: 10.1016/j.jacc.2016.08.010.PMID: 27580689
2. Adelborg K, Grove EL, Sundbøll J, Laursen M, Schmidt M. Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. *Heart*. 2016 Dec 1;102(23):1883-1889. doi: 10.1136/heartjnl-2016-309402.PMID:27406838

3. Grove EL, Würtz M, Schwarz P, Jørgensen NR, Vestergaard P. Gastrointestinal events with clopidogrel: a nationwide population-based cohort study. *J Gen Intern Med.* 2013 Feb;28(2):216-22. doi: 10.1007/s11606-012-2208-0.PMID:22948933
4. Charlot M, Grove EL, Hansen PR, Olesen JB, Ahlehoff O, Selmer C, Lindhardsen J, Madsen JK, Køber L, Torp-Pedersen C, Gislason GH. Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study. *BMJ.* 2011 May 11;342:d2690. doi: 10.1136/bmj.d2690.PMID: 21562004
5. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD. Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. *J Thromb Haemost.* 2011 Jan;9(1):185-91. doi: 10.1111/j.1538-7836.2010.04115.x.PMID: 20955349

Prof. Sigrun Halvorsen, MD, PhD, FESC

1. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, Granger CB, Hanna M, Held C, Husted S, Hylek EM, Jansky P, Lopes RD, Ruzyllo W, Thomas L, Wallentin L. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. *Eur Heart J* 2014;35:1864-72
2. Halvorsen S, Andreotti F, Ten Berg JM, Cattaneo M, Coccheri S, Marchioli R, Morais J, Verheugt FW, De Caterina R. Aspirin Therapy in Primary Cardiovascular Disease Prevention: A Position Paper of the European Society of Cardiology Working Group on Thrombosis. *J Am Coll Cardiol* 2014;64:319-327.
3. Madan M, Halvorsen S, Di Mario C, Tan M, Westerhout CM, Cantor WJ, Le May MR, Borgia F, Piscione F, Scheller B, Armstrong PW, Fernandez-Aviles F, Sanchez PL, Graham JJ, Yan AT, Goodman SG. Relationship Between Time to Invasive Assessment and Clinical Outcomes Among Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Elevation Myocardial Infarction: a Patient-level Analysis of the Randomized Early Routine Invasive Clinical Trials. *JACC Intervention* 2015;8:166-74
4. Halvorsen S, Storey RF, Rocca B, Sibbing D, Ten Berg J, Grove EL, Weiss TW, Collet JP, Andreotti F, Gulba DC, Lip GY, Husted S, Vilahur G, Morais J, Verheugt FW, Lanus A, Al-Shahi Salman R, Steg PG, Huber K; ESC Working Group on Thrombosis. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. *Eur Heart J.* 2016 Oct 27. pii: ehw454.
5. Kvakkestad KM, Wang Fagerland M, Eritsland J, Halvorsen S. Gender differences in all-cause, cardiovascular and cancer mortality during long-term follow-up after acute myocardial infarction; a prospective cohort study. *BMC Cardiovasc Disord.* 2017;17:75

Prof. Bianca Rocca, MD, PhD

1. Patrono C, Rocca B. Type 2 Diabetes, Obesity, and Aspirin Responsiveness. *J Am Coll Cardiol.* 2017 Feb 14;69(6):613-615.
2. Zaccardi F, Rizzi A, Petrucci G, Ciuffardini F, Tanese L, Pagliaccia F, Cavalca V, Ciminello A, Habib A, Rizzo P, Squellerio I, Tremoli E, Rocca B, Pitocco D and Patrono C. In vivo platelet activation and aspirin responsiveness in type 1 diabetes mellitus. *Diabetes.* 2016; 65 (2):503-509. Rocca B corresponding Author.
3. Rocca B and Patrono C. Platelet progenitors: the hidden drug target. *European Heart Journal.* 2015;36(45):3211-3.
4. Patrono C, Rocca B, De Stefano V. Platelet Activation and Inhibition in Polycythemia Vera and Essential Thrombocythemia. *Blood.* 2013;121(10):1701-11.
5. Rocca B, Santilli F, Pitocco D, Mucci L, Petrucci G, Vitacolonna E, Lattanzio S, Mattoscio D, Zaccardi F, Liani R, Vazzana N, Del Ponte A, Ferrante E, Martini F, Cardillo C, Morsetti R, Mirabella M, Ghirlanda G, Davì G, Patrono C. The Recovery of Platelet Cyclooxygenase Activity Explains Interindividual Variability in

Responsiveness to Low-Dose Aspirin in Patients With and Without Diabetes. *Journal Thrombosis and Haemostasis*. 2012; 10(7):1220-30.

Dr. Andrea Rubboli, MD, FESC

1. Rubboli A, Verheugt FW. Reduced dose and reduced exposure to non-vitamin K-antagonist oral anticoagulants: Some considerations on this relationship. *Int J Cardiol*. 2016 Nov 15;223:519-520. doi: 10.1016/j.ijcard.2016.08.207. Epub 2016 Aug 12. PMID: 27552569
2. Rubboli A, Agewall S, Huber K, Lip GY. New-onset atrial fibrillation after recent coronary stenting: Warfarin or non-vitamin K-antagonist oral anticoagulants to be added to aspirin and clopidogrel? A viewpoint. *Int J Cardiol*. 2015 Oct 1;196:133-8. doi: 10.1016/j.ijcard.2015.06.006. Epub 2015 Jun 15. PMID:26093527
3. Rubboli A, Faxon DP, Juhani Airaksinen KE, Schlitt A, Marín F, Bhatt DL, Lip GY. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th Anniversary Overview. *Thromb Haemost*. 2014 Dec;112(6):1080-7. doi: 10.1160/TH14-08-0681. Epub 2014 Oct 9. PMID:25298351
4. Rubboli A, Schlitt A, Kiviniemi T, Biancari F, Karjalainen PP, Valencia J, Laine M, Kirchhof P, Niemelä M, Vikman S, Lip GY, Airaksinen KE; AFCAS Study Group. One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS registry. *Clin Cardiol*. 2014 Jun;37(6):357-64. doi: 10.1002/clc.22254. Epub 2014 Jan 30. PMID:24481953
5. Rubboli A, Magnavacchi P, Guastaroba P, Saia F, Vignali L, Giacometti P, Franco N, Benassi A, Varani E, Campo G, Manari A, De Palma R, Marzocchi A. Antithrombotic management and 1-year outcome of patients on oral anticoagulation undergoing coronary stent implantation (from the Registro Regionale Angioplastiche Emilia-Romagna Registry). *Am J Cardiol*. 2012 May 15;109(10):1411-7. doi: 10.1016/j.amjcard.2012.01.353. Epub 2012 Feb 18. PMID:22342850

Prof. Dr. med. Dirk Sibbing, MHBA, FESC

1. Sibbing D, Massberg S. Antiplatelet strategies in elderly people: still a long way to go. *Lancet*. 2016 Oct 22;388(10055):1962-1964. doi: 10.1016/S0140-6736(16)31387-3. Epub 2016 Aug 28. PMID: 27581529
2. Sibbing D, Kastrati A, Berger PB. Pre-treatment with P2Y12 inhibitors in ACS patients: who, when, why, and which agent? *Eur Heart J*. 2016 Apr 21;37(16):1284-95. doi: 10.1093/eurheartj/ehv717. Epub 2015 Dec 27. PMID: 26712838
3. Sibbing D, Aradi D, Jacobshagen C, Gross L, Trenk D, Geisler T, Orban M, Gori T, Hadamitzky M, Merkely B, Kiss RG, Komócsi A, Dézsi CA, Thalmeier A, Löw A, Holdt L, Teupser D, Ince H, Felix SB, Parma R, Malek L, Horstkotte J, Baylacher M, Schwinger R, Rieber J, Mudra H, Hausleiter J, Huber K, Neumann FJ, Koltowski L, Huczek Z, Mehilli J, Massberg S; TROPICAL-ACS Investigators. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial. *ThrombHaemost*. 2017 Jan 5;117(1):188-195. doi: 10.1160/TH16-07-0557. Epub 2016 Sep 22. PMID: 27652610
4. Aradi D, Kirtane A, Bonello L, Gurbel PA, Tantry US, Huber K, Freynhofer MK, ten Berg J, Janssen P, Angiolillo DJ, Siller-Matula JM, Marcucci R, Patti G, Mangiacapra F, Valgimigli M, Morel O, Palmerini T, Price MJ, Cuisset T, Kastrati A, Stone GW, Sibbing D. Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. *Eur Heart J*. 2015 Jul 14;36(27):1762-71. doi: 10.1093/eurheartj/ehv104. Epub 2015 Apr 20. PMID: 25896078
5. Mayer K, Bernlochner I, Braun S, Schulz S, Orban M, Morath T, Cala L, Hoppmann P, Schunkert H, Laugwitz KL, Kastrati A, Sibbing D. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. *J Am CollCardiol*. 2014 Sep 2;64(9):863-71. doi: 10.1016/j.jacc.2014.05.049. PMID: 25169169

Associate Prof. Jolanta Siller-Matula, MD, PhD

1. Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, Stankowska K, Buszko K, Navarese EP, Jilma B, Siller-Matula JM, Marszall MP, Rosc D, Kozinski M. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: The randomized, double-blind, placebo-controlled impression trial. *Eur Heart J*. 2016;37:245-252
2. Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J, Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA, Working Group on On-Treatment Platelet R. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. *J Am Coll Cardiol*. 2013;62:2261-2273
3. Siller-Matula JM, Merhi Y, Tanguay JF, Duerschmied D, Wagner DD, McGinness KE, Pendergrast PS, Chung JK, Tian X, Schaub RG, Jilma B. ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion. *Arterioscler Thromb Vasc Biol* 2012;32(4):902-9.
4. Siller-Matula JM, Delle-Karth G, Lang IM, Neunteufl T, Kozinski M, Kubica J, Maurer G, Linkowska K, Grzybowski T, Huber K, Jilma B. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. *J Thromb Haemost* 2012;10(4):529-42.
5. Siller-Matula JM. Hemorrhagic complications associated with aspirin: An underestimated hazard in clinical practice? *JAMA*. 2012;307:2318-2320

Associate Prof Walter Speidl

1. Krychtiuk KA, Kaun C, Hohensinner PJ, Stojkovic S, Seigner J, Kastl SP, Zuckermann A, Eppel W, Rauscher S, de Martin R, Maurer G, Huber K, Wojta J, Speidl WS. Anti-thrombotic and pro-fibrinolytic effects of levosimendan in human endothelial cells in vitro. *Vascul Pharmacol*. 2017 Mar;90:44-50. doi:10.1016/j.vph.2017.02.003. Epub 2017 Feb 10. PubMed PMID: 28192257.
2. Krychtiuk KA, Lenz M, Koller L, Honeder MC, Wutzlhofer L, Zhang C, Chi L, Maurer G, Niessner A, Huber K, Wojta J, Heinz G, Speidl WS. Monocyte subset distribution is associated with mortality in critically ill patients. *Thromb Haemost*. 2016 Oct 28;116(5):949-957. Epub 2016 Sep 8. PubMed PMID: 27604519.
3. Thaler B, Hohensinner PJ, Krychtiuk KA, Matzneller P, Koller L, Brekalo M, Maurer G, Huber K, Zeitlinger M, Jilma B, Wojta J, Speidl WS. Differential in vivo activation of monocyte subsets during low-grade inflammation through experimental endotoxemia in humans. *Sci Rep*. 2016 Jul 22;6:30162. doi: 10.1038/srep30162. PubMed PMID: 27444882; PubMed Central PMCID: PMC4957086.
4. Krychtiuk KA, Ruhittel S, Hohensinner PJ, Koller L, Kaun C, Lenz M, Bauer B, Wutzlhofer L, Draxler DF, Maurer G, Huber K, Wojta J, Heinz G, Niessner A, Speidl WS. Mitochondrial DNA and Toll-Like Receptor-9 Are Associated With Mortality in critically Ill Patients. *Crit Care Med*. 2015 Dec;43(12):2633-41. doi:10.1097/CCM.0000000000001311. PubMed PMID: 26448617.
5. Krychtiuk KA, Kastl SP, Pfaffenberger S, Pongratz T, Hofbauer SL, Wonnerth A, Katsaros KM, Goliash G, Gaspar L, Huber K, Maurer G, Dostal E, Oravec S, Wojta J, Speidl WS. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. *Atherosclerosis*. 2014 Dec;237(2):589-96. doi: 10.1016/j.atherosclerosis.2014.10.015. Epub 2014 Oct 18. PubMed PMID: 25463093; PubMed Central PMCID: PMC4270455.

Prof. Robert Storey, FESC

1. Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RF. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. *Thromb Haemost* 2017 in press.
2. Thomas MR, Morton AC, Hossain R, Chen B, Luo L, Shahari NN, Hua P, Beniston RG, Judge HM, Storey RF. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. *Thromb Haemost* 2016; 116:96-102.
3. Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Braunwald E and Sabatine MS. Platelet Inhibition with Ticagrelor 60 mg Compared with 90 mg Twice-daily in the PEGASUS-TIMI 54 study. *J Am Coll Cardiol* 2016; 67:1145-54.
4. Thomas MR, Outteridge SN, Ajjan RA, Phoenix F, Sangha GK, Faulkner RE, Ecob R, Judge HM, Khan H, West LE, Dockrell DH, Sabroe I, Storey RF. Platelet P2Y12 inhibitors reduced systemic inflammation and its prothrombotic effects in an experimental human model. *Arterioscler Thromb Vasc Biol* 2015; 35:2562-2570.
5. Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, PEGASUS-TIMI 54 Steering Committee and Investigators. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction. *N Engl J Med* 2015; 372: 1791-800.

Dr. Germma Vilahur, PhD, FESC,

6. Vilahur G, Gutierrez M, Casani L, Cubedo J, Capdevila A, Pons-Lladó G, Carreras F, Hidalgo A, Badimon L. Hypercholesterolemia abolishes high-density lipoproteins-related cardioprotective effects in myocardial infarction. *Journal of the American College of Cardiology* Dec 1;66(21):2469-2470; 2015
7. Vilahur G, Gutiérrez M, Casani L, Varela L, Capdevila A, Pons-Lladó G, Carreras F, Carlsson L, Hidalgo A, Badimon L. Response by Vilahur et al to Letters Regarding Article, "Protective Effects of Ticagrelor on Myocardial Injury After Infarction". *Circulation* Apr 25;135(17):e1004-e1005; 2017
8. Vilahur G, S. Ben-Aicha, Badimon L. New insights into the role of adipose tissue in thrombosis *Cardiovascular Research* (in press) 2017
9. Padró T, Cubedo J, Camino S, Béjar MT, Ben-Aicha S, Mendieta G, Escolà-Gil JC, Escate R, Gutiérrez M, Casani L, Badimon L, Vilahur G. Detrimental Effect of Hypercholesterolemia on High-Density Lipoprotein Particle Remodeling in Pigs. *J Am Coll Cardiol*. 2017;70(2):165-178. 2017
10. Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, Rocca B, Siegbahn A, Storey R, Vilahur G. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. A Consensus Document of the Task Force on Antiplatelet Agents of the Working Group on Thrombosis of the European Society of Cardiology. *J Am Coll Cardiol*. 2017 Oct 3;70(14):1760-1776